Business
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentation\nCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast on Wednesday, September 28, 2022. The event will highlight WVE-006, Wave’s A-to-I RNA base editing oligonucleotide (“AIMer”) candidate for the treatment of alpha-1 antitrypsin deficiency (AATD), provide perspectives from an expert in AATD, and outline future therapeutic applications of Wave’s best-in-class RNA editing capability. “Towards the Clinic: Spotlight on RNA Editing for AATD” Date: Wednesday, September 28, 2022Time: 10:00 a.m. – 11:30 a.m. EDT The event will feature presentations from the Wave Life Sciences management team including Paul Bolno, MD, MBA, President and Chief Executive Officer, Paloma Giangrande, PhD, VP, Platform Discovery Sciences, Biology, and Chandra Vargeese, PhD, Chief Technology Officer and Head of Platform Discovery Sciences. Dr. D. Kyle Hogarth, Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at the University of Chicago, will also present. Dr. Hogarth is a well-known clinical expert in the treatment of people living with AATD. He serves as the Director of the Alpha-1 Clinical Resource Center at the University of Chicago and was co-author of the 2016 clinical practice guidelines for AATD. A Q&A session will follow the presentations. A link to register for the upcoming event is available here. A live webcast of the event will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website. About WVE-006WVE-006 is a PN-modified GalNAc-conjugated investigational development candidate for the treatment of alpha-1 antitrypsin deficiency (AATD), designed to correct the mutant SERPINA1 Z allele transcript to address both liver and lung manifestations of disease. WVE-006 is a first-in-class RNA editing candidate (AIMer) and the most advanced program currently in development using an oligonucleotide to harness an endog...